The role of bisphosphonates in multiple myeloma

Jessica Levy, G. David Roodman

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Multiple myeloma (MM) is the second most common hematologic malignancy and the most common malignancy to involve bone. More than 85% of patients with MM have bone involvement, which can be devastating. Bisphosphonate therapy is the mainstay of treatment for MM bone disease; it has decreased the frequency of skeletal events in MM and delayed their development. Further, the toxicity of these drugs is low and generally manageable. Whether bisphosphonates have any antitumor effects in MM patients (in contrast to what has been reported in preclinical models) is unclear and requires further study. Although bisphosphonates have been extremely effective for treating MM bone disease, they do not completely inhibit the development of skeletal events, but only decrease them significantly. Other antiresorptive agents now being developed may further enhance the quality of life for MM patients when used in combination with bisphosphonates.

Original languageEnglish (US)
Pages (from-to)108-112
Number of pages5
JournalCurrent Hematologic Malignancy Reports
Volume4
Issue number2
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Diphosphonates
Multiple Myeloma
Bone Diseases
Bone Density Conservation Agents
Bone and Bones
Hematologic Neoplasms
Drug-Related Side Effects and Adverse Reactions
Quality of Life
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

The role of bisphosphonates in multiple myeloma. / Levy, Jessica; Roodman, G. David.

In: Current Hematologic Malignancy Reports, Vol. 4, No. 2, 2009, p. 108-112.

Research output: Contribution to journalArticle

@article{4dadf846306f4d99aa9d79b1aed3082a,
title = "The role of bisphosphonates in multiple myeloma",
abstract = "Multiple myeloma (MM) is the second most common hematologic malignancy and the most common malignancy to involve bone. More than 85{\%} of patients with MM have bone involvement, which can be devastating. Bisphosphonate therapy is the mainstay of treatment for MM bone disease; it has decreased the frequency of skeletal events in MM and delayed their development. Further, the toxicity of these drugs is low and generally manageable. Whether bisphosphonates have any antitumor effects in MM patients (in contrast to what has been reported in preclinical models) is unclear and requires further study. Although bisphosphonates have been extremely effective for treating MM bone disease, they do not completely inhibit the development of skeletal events, but only decrease them significantly. Other antiresorptive agents now being developed may further enhance the quality of life for MM patients when used in combination with bisphosphonates.",
author = "Jessica Levy and Roodman, {G. David}",
year = "2009",
doi = "10.1007/s11899-009-0015-4",
language = "English (US)",
volume = "4",
pages = "108--112",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "2",

}

TY - JOUR

T1 - The role of bisphosphonates in multiple myeloma

AU - Levy, Jessica

AU - Roodman, G. David

PY - 2009

Y1 - 2009

N2 - Multiple myeloma (MM) is the second most common hematologic malignancy and the most common malignancy to involve bone. More than 85% of patients with MM have bone involvement, which can be devastating. Bisphosphonate therapy is the mainstay of treatment for MM bone disease; it has decreased the frequency of skeletal events in MM and delayed their development. Further, the toxicity of these drugs is low and generally manageable. Whether bisphosphonates have any antitumor effects in MM patients (in contrast to what has been reported in preclinical models) is unclear and requires further study. Although bisphosphonates have been extremely effective for treating MM bone disease, they do not completely inhibit the development of skeletal events, but only decrease them significantly. Other antiresorptive agents now being developed may further enhance the quality of life for MM patients when used in combination with bisphosphonates.

AB - Multiple myeloma (MM) is the second most common hematologic malignancy and the most common malignancy to involve bone. More than 85% of patients with MM have bone involvement, which can be devastating. Bisphosphonate therapy is the mainstay of treatment for MM bone disease; it has decreased the frequency of skeletal events in MM and delayed their development. Further, the toxicity of these drugs is low and generally manageable. Whether bisphosphonates have any antitumor effects in MM patients (in contrast to what has been reported in preclinical models) is unclear and requires further study. Although bisphosphonates have been extremely effective for treating MM bone disease, they do not completely inhibit the development of skeletal events, but only decrease them significantly. Other antiresorptive agents now being developed may further enhance the quality of life for MM patients when used in combination with bisphosphonates.

UR - http://www.scopus.com/inward/record.url?scp=63549123413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63549123413&partnerID=8YFLogxK

U2 - 10.1007/s11899-009-0015-4

DO - 10.1007/s11899-009-0015-4

M3 - Article

C2 - 20425422

AN - SCOPUS:63549123413

VL - 4

SP - 108

EP - 112

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 2

ER -